The Current Ratio as of November 2024 (TTM) for Emergent BioSolutions Inc. (EBS) is 2.88

According to Emergent BioSolutions Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 2.88. This represents a change of 89.92% compared to the average of 1.51 of the last 4 quarters.

Emergent BioSolutions Inc. (EBS) Historical Current Ratio (quarterly & annually)

How has EBS Current Ratio performed in the past?

The mean historical Current Ratio of Emergent BioSolutions Inc. over the last ten years is 3.45. The current 2.88 Current Ratio has changed 8.23% with respect to the historical average. Over the past ten years (40 quarters), EBS's Current Ratio was at its highest in in the September 2017 quarter at 7.37. The Current Ratio was at its lowest in in the September 2023 quarter at 0.53.

Emergent BioSolutions Inc. (EBS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Emergent BioSolutions Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Emergent BioSolutions Inc. (EBS) Average Current Ratio

How has EBS Current Ratio performed in the past?

The current Current Ratio of Emergent BioSolutions Inc. (EBS) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Emergent BioSolutions Inc. (EBS) Current Ratio vs. Peers

How is EBS’s Current Ratio compared to its peers?

Emergent BioSolutions Inc.’s Current Ratio is less than Zoetis Inc. (3.69), greater than PetIQ, Inc. (2.58), greater than Bausch Health Companies Inc. (1.19), less than Neurocrine Biosciences, Inc. (4.37), greater than Akanda Corp. (1.41), greater than Lifecore Biomedical, Inc. (1.83), less than Prestige Consumer Healthcare Inc. (3.56), less than Intra-Cellular Therapies, Inc. (7.66), greater than Indivior PLC (0.83), less than Alkermes plc (3.45), greater than Cumberland Pharmaceuticals Inc. (1.13), less than Deciphera Pharmaceuticals, Inc. (4.19), greater than Collegium Pharmaceutical, Inc. (0.97), greater than DURECT Corporation (0.71),

Build a custom stock screener for Emergent BioSolutions Inc. (EBS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Emergent BioSolutions Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Emergent BioSolutions Inc. (EBS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Emergent BioSolutions Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.